IPHEX 2017, the 5th edition of Mega Pharma Show organized by Pharmaceuticals Export Promotion Council of India is now coming to Hyderabad. The event is scheduled at HITEX Exhibition Centre from 27-29 April 2017.
“We are pleased to bring IPHEX to Hyderabad,” said Mr. Madan Mohan Reddy, Chairman, Pharmexcil.
“IPHEX is the largest global showcase for the Indian pharmaceutical and healthcare sector to help explore international business opportunities and enhance the Indian pharmaceutical exports. Overseas buyers are coming from over 100 countries and we shall showcase India’s comprehensive production range of APIs, formulations, nutraceuticals, excipients, veterinary drugs, biological and ayush products at the show,” informed Mr. Reddy.
With over 600 International buyers set to meet 300 Indian companies over action packed 3 days, IPHEX 2017 will catalyze pharma growth for Indian exporters.
The Indian pharmaceuticals market is the 3rd largest in terms of volume and 11th largest in terms of value. India is the largest provider of generic drugs globally with the Indian generics accounting for 20 per cent of global exports in terms of volume.
As India already has a significant presence of generics in US, European and African markets, events like IPHEX create visibility and help overseas buyers from emerging markets to come and explore sourcing opportunities.
Speaking to the media, Mr. Reddy further said,” Indian Pharma sector is set for a quantum leap. India has 700 drug manufacturing units registered with the US Food and Drug Administration (USFDA) and over 30 per cent of abbreviated new drug applications (ANDAs) granted by the USFDA in 2016 were from India. We are hopeful of achieving a double digit export growth in the near future and reach USD 20 million exports by 2020.”
Mr. Udaya Bhaskar, Director General, Pharmexcil highlighted various initiatives being planned at IPHEX 2017,
For the first time, we are creating an International Regulators lounge on the show floor, where Indian companies can interact with overseas drug regulators and can discuss about FDA regulations, drug registration processes. Government Procurement procedures and market potential in their countries. Pharmexcil has also created an Innovation lounge for meaningful interactions between the Indian Pharma Industry and R&D experts from National Research Institutes such as IICT.NCL etc. These initiatives will help Industry hone their product development skills for a sustained foray in global markets,” informed Mr. Udaya Bhaskar.
He further added that seminars are also being organized on Challenges being faced in International Regulations, International Government Procurement Mechanism, and Strategies to reduce import dependence of Intermediates, KSMs and APIs.
“IPHEX 2017 will help Telangana and Andhra Pradesh pharma companies exhibit their expertise in APIs, formulations, vaccines and other solutions to overseas buyers and increase exports from the region,” said Mr. Ramesh Babu, Chairman -IPHEX 2017.
“Mumbai, Ahmedabad, are often shown as key Indian pharma hubs. States of Telangana and Andhra Pradesh play a significant role in Indian pharma sector exports. Hyderabad has over 400 bulk drug manufacturers and has 245 USFDA approved plants, the highest outside US. We hope to bring more investments in the state by showcasing the state of the art manufacturing facilities,” concluded Mr. Babu.
